After attending medical school at the University of Maryland, Dr. Karli completed his residency in Physical Medicine and Rehabilitation at Harvard Medical School. Subsequently, he joined the faculty at Harvard, serving as an Attending Physician with the Department of PM&R at Spaulding Rehabilitation Hospital, as well as working in the Department of Orthopedic Surgery at Mass General Hospital.

After Harvard, in 2003, Dr Karli was recruited by the Steadman Clinic in Vail Colorado where he adopted and later perfected the use of autologous-based cellular therapies like Platelet Rich Plasma (PRP) and Bone Marrow Cell Concentrate (BMC), designed to improve patient outcomes. He led national efforts to refine the practice of regenerative medicine, and published pivotal clinical results while lecturing extensively on the importance of dose, response and data supported results. His practice grew substantially and includes treating elite-level and professional athletes. As a result, Dr. Karli has been featured in media publications such as the Wall Street Journal, New York Times, ESPN Magazine and Denver Magazine.

Dr. Karli recognized early in his career that understanding the composition of regenerative biologic preparations used in treating his patients would be critical to refining his practice of medicine. He also realized that a “one size fits all” approach to creating these therapeutic preparations wouldn’t meet the need for an evidence-based, precise medical approach. As a result, he founded Greyledge Technologies in 2012, a biotech company focused on optimizing production of cellular therapeutics. In support of this concept for regenerative medicine, he completed formal Laboratory Director training and obtained his MBA at the Daniels College of Business at the University of Denver.

Dr. Karli has been recognized for his work in the regenerative medicine field. 

• TOBI Presentation 2022